Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v15-EN | Version v7-FR | |
|---|---|---|
| Language | English | French |
| Date Updated | 2022-10-07 | 2022-07-08 |
| Drug Identification Number | 02241933 | 02241933 |
| Brand name | VIOKACE | VIOKACE |
| Common or Proper name | Pancrelipase | Pancrelipase |
| Company Name | NESTLE ENTERPRISES S.A. | NESTLE ENTERPRISES S.A. |
| Ingredients | AMYLASE PROTEASE LIPASE | AMYLASE PROTEASE LIPASE |
| Strength(s) | 113400UNIT 112500UNIT 20880UNIT | 113400UNIT 112500UNIT 20880UNIT |
| Dosage form(s) | TABLET | TABLET |
| Route of administration | ORAL ORAL | ORAL ORAL |
| Packaging size | 100 tablet bottles | 100 tablet bottles |
| ATC code | A09AA | A09AA |
| ATC description | DIGESTIVES, INCL ENZYMES | DIGESTIVES, INCL ENZYMES |
| Reason for shortage | Shortage of an active ingredient. | Shortage of an active ingredient. |
| Anticipated start date | 2022-08-01 | 2022-08-01 |
| Actual start date | 2022-09-01 | |
| Estimated end date | Unknown | |
| Actual end date | 2022-10-06 | |
| Shortage status | Resolved | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | We are pleased to tell you that Viokace 10440 and Viokace 20880 stock is now available for sale. Please place your orders as you normally would (either through EDI order by contacting Customer Service at): orders@apcipharma.com. Thank you for your patience. | There is an anticipated shortage of Viokace 20,880 tablets estimated for August 1,2022. Nestle Health Science is actively working on resolving supply chain constraints and further updates will be provided as they become available. |
| Health Canada comments |